16 completed. 16 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 16 |
| Phase 3 | 4 | Completed 4 |
Follow Livedoid Vasculopathy: new trials by email Literature Review of Livedoid Vasculopathy trials Research Report on Livedoid Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | Civi Biopharma, Inc. | 34 | 2019-03-07 | 2025-05-25 |
| Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Alprostadil, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | 35 | 2014-11-01 | 2016-03-22 |
| Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Selexipag, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | Actelion | 74 | 2014-10-31 | 2026-06-03 |
| "As Required" Oral Sildenafil in Raynaud's Phenomenon Sildenafil 40 mg, Sildenafil 80 mg, Placebo - Raynaud's Phenomenon | Phase 2 / Phase 3 | Completed | University Hospital, Grenoble | 41 | 2013-11-01 | 2016-01-18 |
| Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Riociguat (Adempas, BAY63-2521), Placebo - Raynaud Disease | Phase 2 | Completed | Bayer | 23 | 2013-10-01 | 2014-06-16 |
| A Two-Part Study of BOTOX® Therapy for Ischemic Digits onabotulinum toxin type-A - Raynaud's Disease | Phase 2 | Completed | Southern Illinois University | 48 | 2011-05-01 | 2019-01-08 |
| Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Udenafil or Amlodipine - Raynaud Phenomenon | Phase 2 / Phase 3 | Completed | Seoul National University Hospital | 29 | 2011-01-01 | 2012-12-11 |
| PF-00489791 For The Treatment Of Raynaud's PF-00489791 - Raynaud's Disease, Peripheral Vascular Disease | Phase 2 | Completed | Pfizer | 243 | 2010-08-04 | 2018-05-16 |
| Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease SLx-2101, Placebo - Raynaud's Disease | Phase 2 | Completed | Response Pharmaceuticals | 17 | 2007-06-01 | 2023-11-18 |
| Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Nitroglycerin - Raynaud's Disease | Phase 2 | Completed | MediQuest Therapeutics | 15 | 2007-05-01 | 2007-12-24 |
| Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome vardenafil, Placebo - Raynaud Syndrome | Phase 2 / Phase 3 | Completed | University of Cologne | 57 | 2006-11-01 | 2011-02-08 |
| Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon MQX-503 - Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma | Phase 2 | Completed | MediQuest Therapeutics | 15 | 2006-07-01 | 2007-05-30 |
| Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Ginkgo biloba extract EGb 761 - Raynaud Disease | Phase 2 | Completed | VSM Geneesmiddelen b.v. | 41 | 2005-11-01 | 2017-05-22 |
| Lab Study of MQX-503 in Treatment of Raynaud's topical organogel with nitroglycerin - Raynaud Disease, Raynaud Disease Secondary to Scleroderma | Phase 2 / Phase 3 | Completed | MediQuest Therapeutics | 36 | 2004-11-01 | 2007-05-30 |
| Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction Cialis - Systemic Sclerosis | Phase 2 | Completed | University of Medicine and Dentistry of New Jersey | 120 | 2001-07-01 | 2008-06-30 |
Raynaud Disease (16) · Scleroderma, Systemic (7) · Scleroderma, Diffuse (4) · Autoimmune Diseases (1) · Ischemia (1) · Peripheral Vascular Diseases (1) · Signs and Symptoms (1)
Cardiovascular Diseases (16) · Embolism and Thrombosis (16) · Skin Diseases (16) · Skin Diseases, Vascular (16) · Skin and Connective Tissue Diseases (16) · Thrombosis (16) · Vascular Diseases (16) · Peripheral Vascular Diseases (15) · Connective Tissue Diseases (9) · Pathological Conditions, Signs and Symptoms (2) · Scleroderma, Systemic (2) · Immune System Diseases (1) · Pathologic Processes (1)
Nitroglycerin (2) · Alprostadil (1) · Amlodipine (1) · Botulinum Toxins, Type A (1) · Ginkgo Extract (1) · Ginkgo biloba extract (1) · Iloprost (1) · PF-00489791 (1) · Sildenafil Citrate (1) · Tadalafil (1) · Vardenafil Dihydrochloride (1) · compound 21 (1) · riociguat (1) · selexipag (1) · udenafil (1)
MediQuest Therapeutics (3) · Actelion (1) · Bayer (1) · Civi Biopharma, Inc. (1) · NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) (1) · Pfizer (1) · Response Pharmaceuticals (1) · Seoul National University Hospital (1) · Southern Illinois University (1) · University Hospital, Grenoble (1) · University of Cologne (1) · University of Medicine and Dentistry of New Jersey (1) · VSM Geneesmiddelen b.v. (1) · Vicore Pharma AB (1)
United States (8) · Germany (5) · France (2) · South Korea (2) · United Kingdom (2) · Canada (1) · Colombia (1) · Czechia (1) · Hungary (1) · Mexico (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1)
Ariane Herrick, MD (1) · Barbara Troupin, MD, MBA (1) · Carin Dugowson, MD, MPH (1) · Eun Bong Lee, MD PhD (1) · Eun Young Lee, MD PhD (1) · Jin Kyun Park, MD (1) · Laura K Hummers, MD (1) · Lee Shapiro, MD (1) · Leslie Klaff, MD (1) · M Baumaker, MD (1) · Michael W Neumeister, MD (1) · Ralph Preiss, MD (1)
PMID 24352340, PMID 29193819, PMID 30383134, PMID 33998674, PMID 35894657, PMID 37929840
2005 (1), 2019 (1)